LPI-labile Plasma Iron in Iron Overload

Best Pract Res Clin Haematol. 2005 Jun;18(2):277-87. doi: 10.1016/j.beha.2004.10.003.

Abstract

Labile plasma iron (LPI) represents a component of non-transferrin-bound iron (NTBI) that is both redox-active and chelatable, capable of permeating into organs and inducing tissue iron overload. It appears in various types of hemosiderosis (transfusional and non-transfusional) and in other iron-overload conditions. Sustained levels of LPI could over time compromise organ (e.g. heart) function and patient survival. With the advent of methods for measuring LPI in the clinical setting, it has become possible to assess the implications of LPI in the management of iron overload based on regimens of iron chelation. As LPI is detected primarily in patients with transfusional iron overload and other forms of hemosiderosis, we review here regimens of iron chelation with deferrioxamine and deferiprone (separately or combined) in terms of their efficacy in minimizing daily exposure to LPI in thalassemia major and thalassemia intermedia patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Deferiprone
  • Humans
  • Iron / blood*
  • Iron / metabolism
  • Iron Chelating Agents / metabolism
  • Iron Chelating Agents / therapeutic use
  • Iron Overload / metabolism*
  • Oxidation-Reduction
  • Pyridones / therapeutic use
  • Thalassemia / blood*
  • Thalassemia / drug therapy
  • Thalassemia / etiology
  • beta-Thalassemia / blood
  • beta-Thalassemia / drug therapy

Substances

  • Iron Chelating Agents
  • Pyridones
  • Deferiprone
  • Iron